ScripScrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. GSK Becomes Surface Oncology’s Latest B
ScripReturns from newly public biotechnology companies are far below gains from US biotech stocks in general, but that's not stopping drug developers from filing for initial public offerings, including fiv
ScripThe US market for initial public offerings by biopharma companies in 2019 got off to a slow start in January, but eight drug developers went public in February. However, following the news that US FDA
ScripThe US market for initial public offerings by biopharmaceutical companies didn't get into full gear until February, but seven companies rushed to push their IPOs through the open window this month. Ne